Zebinix Europska Unija - hrvatski - EMA (European Medicines Agency)

zebinix

bial - portela & ca, s.a. - eslikarbazepin acetat - epilepsija - antiepileptici sredstva, - zebinix je indiciran kao pomoćna terapija kod odraslih, adolescenata i djece iznad 6 godina, s parcijalnim napadajima sa ili bez sekundarne generalizacije.

Zonisamide Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

zonisamide mylan

mylan pharmaceuticals limited - zonisamid - epilepsija - antiepileptici sredstva, - monoterapija u liječenju parcijalnih napadaja napadaja sa ili bez sekundarne generalizacije kod odraslih s prvi put utvrđenom epilepsijom;dodatni terapija u liječenju parcijalnih napadaja epileptičnih napadaja sa ili bez sekundarne generalizacije kod odraslih, djece i adolescenata u dobi od 6 godina i više.

Bosentan Alpha-Medical 125 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bosentan alpha-medical 125 mg filmom obložene tablete

alpha-medical d.o.o., dragutina golika 36, zagreb - bosentanum - filmom obložena tableta - 125 mg - urbroj: svaka filmom obložena tableta sadrži 125 mg bosentana (u obliku hidrata)

Bosentan Alpha-Medical 62,5 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bosentan alpha-medical 62,5 mg filmom obložene tablete

alpha-medical d.o.o., dragutina golika 36, zagreb - bosentanum - filmom obložena tableta - 62,5 mg - urbroj: svaka filmom obložena tableta sadrži 62,5 mg bosentana (u obliku hidrata)

Pelmeg Europska Unija - hrvatski - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenija - Иммуностимуляторы, - za smanjenje trajanja нейтропении i frekvencije фебрильной нейтропении protiv kemoterapije.

Flucelvax Tetra Europska Unija - hrvatski - EMA (European Medicines Agency)

flucelvax tetra

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - gripa, ljudska - virus gripe, инактивированная, split ili površinski antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra treba primjenjivati u skladu sa službenim preporukama.

Cegfila (previously Pegfilgrastim Mundipharma) Europska Unija - hrvatski - EMA (European Medicines Agency)

cegfila (previously pegfilgrastim mundipharma)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenija - Иммуностимуляторы, - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).

Jayempi Europska Unija - hrvatski - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.